{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:46:23Z","timestamp":1790023583906,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,6,6]],"date-time":"2013-06-06T00:00:00Z","timestamp":1370476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s10147-013-0573-2","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T07:52:18Z","timestamp":1370418738000},"page":"544-548","source":"Crossref","is-referenced-by-count":28,"title":["NRAS mutations in primary and metastatic melanomas of Japanese patients"],"prefix":"10.1007","volume":"19","author":[{"given":"Hisashi","family":"Uhara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Kiniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,6]]},"reference":[{"key":"573_CR1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1615\/CritRevOncog.v17.i1.70","volume":"17","author":"M Roring","year":"2012","unstructured":"Roring M, Brummer T (2012) Aberrant b-raf signaling in human cancer\u201410\u00a0years from bench to bedside. Crit Rev Oncog 17:97\u2013121","journal-title":"Crit Rev Oncog"},{"key":"573_CR2","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2011","unstructured":"Curtin JA, Fridlyand J, Kageshita T et al (2011) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135\u20132147","journal-title":"N Engl J Med"},{"key":"573_CR3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with braf v600e mutation. N Engl J Med 364:2507\u20132516","journal-title":"N Engl J Med"},{"key":"573_CR4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.jid.5700026","volume":"126","author":"VK Goel","year":"2006","unstructured":"Goel VK, Lazar AJ, Warneke CL et al (2006) Examination of mutations in braf, nras, and pten in primary cutaneous melanoma. J Invest Dermatol 126:154\u2013160","journal-title":"J Invest Dermatol"},{"key":"573_CR5","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","volume":"118","author":"JA Jakob","year":"2012","unstructured":"Jakob JA, Bassett RL Jr, Ng CS et al (2012) Nras mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118:4014\u20134023","journal-title":"Cancer"},{"key":"573_CR6","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","volume":"164","author":"JH Lee","year":"2011","unstructured":"Lee JH, Choi JW, Kim YS (2011) Frequencies of braf and nras mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164:776\u2013784","journal-title":"Br J Dermatol"},{"key":"573_CR7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.0022-202X.2005.23788.x","volume":"125","author":"LA Akslen","year":"2005","unstructured":"Akslen LA, Angelini S, Straume O et al (2005) Braf and nras mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125:312\u2013317","journal-title":"J Invest Dermatol"},{"key":"573_CR8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","volume":"24","author":"B Devitt","year":"2011","unstructured":"Devitt B, Liu W, Salemi R et al (2011) Clinical outcome and pathological features associated with nras mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24:666\u2013672","journal-title":"Pigment Cell Melanoma Res"},{"key":"573_CR9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","volume":"16","author":"E Edlundh-Rose","year":"2006","unstructured":"Edlundh-Rose E, Egyhazi S, Omholt K et al (2006) Nras and braf mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16:471\u2013478","journal-title":"Melanoma Res"},{"key":"573_CR10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","volume":"17","author":"JA Ellerhorst","year":"2011","unstructured":"Ellerhorst JA, Greene VR, Ekmekcioglu S et al (2011) Clinical correlates of nras and braf mutations in primary human melanoma. Clin Cancer Res 17:229\u2013235","journal-title":"Clin Cancer Res"},{"key":"573_CR11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","volume":"48","author":"L Si","year":"2012","unstructured":"Si L, Kong Y, Xu X et al (2012) Prevalence of braf v600e mutation in Chinese melanoma patients: large scale analysis of braf and nras mutations in a 432-case cohort. Eur J Cancer 48:94\u2013100","journal-title":"Eur J Cancer"},{"key":"573_CR12","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1038\/jid.2012.64","volume":"132","author":"QM Zhou","year":"2012","unstructured":"Zhou QM, Li W, Zhang X et al (2012) The mutation profiles of common oncogenes involved in melanoma in southern china. J Invest Dermatol 132:1935\u20131937","journal-title":"J Invest Dermatol"},{"key":"573_CR13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Schadendorf D, Berking C et al (2013) Mek162 for patients with advanced melanoma harbouring nras or val600 braf mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14:249\u2013256","journal-title":"Lancet Oncol"},{"key":"573_CR14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jdermsci.2012.03.005","volume":"66","author":"A Ashida","year":"2012","unstructured":"Ashida A, Uhara H, Kiniwa Y et al (2012) Assessment of braf and kit mutations in Japanese melanoma patients. J Dermatol Sci 66:240\u2013242","journal-title":"J Dermatol Sci"},{"key":"573_CR15","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","volume":"30","author":"M Colombino","year":"2012","unstructured":"Colombino M, Capone M, Lissia A et al (2012) Braf\/nras mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30:2522\u20132529","journal-title":"J Clin Oncol"},{"key":"573_CR16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","volume":"13","author":"GS Falchook","year":"2012","unstructured":"Falchook GS, Lewis KD, Infante JR et al (2012) Activity of the oral mek inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782\u2013789","journal-title":"Lancet Oncol"},{"key":"573_CR17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/1078-0432.CCR-11-1491","volume":"18","author":"JM Kirkwood","year":"2012","unstructured":"Kirkwood JM, Bastholt L, Robert C et al (2012) Phase ii, open-label, randomized trial of the mek1\/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 18:555\u2013567","journal-title":"Clin Cancer Res"},{"key":"573_CR18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883\u2013892","journal-title":"N Engl J Med"},{"key":"573_CR19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc2627","volume":"9","author":"CA Klein","year":"2009","unstructured":"Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9:302\u2013312","journal-title":"Nat Rev Cancer"},{"key":"573_CR20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","volume":"439","author":"DB Solit","year":"2006","unstructured":"Solit DB, Garraway LA, Pratilas CA et al (2006) Braf mutation predicts sensitivity to mek inhibition. Nature 439:358\u2013362","journal-title":"Nature"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0573-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-013-0573-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0573-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T10:37:31Z","timestamp":1559126251000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-013-0573-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,6]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1007\/s10147-013-0573-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,6]]}}}